Lewis B. Silverman
Associate ProfessorÂ
Pediatric Hematologic MalignanciesÂ
Dana-Farber Cancer Institute
United States of America
Biography
Dr. Silverman received his MD from Harvard Medical School in 1991 and training in pediatrics at Children's Hospital Boston in 1994. He subsequently completed a fellowship in pediatric hematology-oncology at Children's Hospital and DFCI. In 1997, he became an attending physician in pediatric oncology at Children's Hospital and DFCI, where he currently is medical director of the Inpatient Oncology Serive and chief of the Pediatric Hematologic Malignancy Service. He is the principal investigator of the DFCI ALL Consortium, a multi-institutional group conducting clinical trials in children with newly diagnosed and relapsed ALL.
Research Interest
Acute lymphoblastic leukemia
Publications
-
Pikman Y, Alexe G, Roti G, Saur Conway A, Furman A, Lee ES, Place AE, Kim S, Saran C, Modiste R, Weinstock DM, Harris M, Kung AL, Silverman LB, Stegmaier K. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res 2017.Â
-
Finkelstein Y, Blonquist TM, Vijayanathan V, Stevenson KE, Neuberg DS, Silverman LB, Vrooman LM, Sallan SE, Cole PD. A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer 2016.
-
Sands SA, Harel BT, Savone M, Kelly K, Vijayanathan V, Welch JG, Vrooman L, Silverman LB, Cole PD. Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia. Support Care Cancer 2016; 25:449-457.Â
